A Study to Evaluate the Safety and Effectiveness of ALKS 2680 in Subjects With Narcolepsy Type 1 (ALKS 2680-201)
Study sponsor: Alkermes, Inc.
Primary completion is the date data collection ends for the main study measures, not when results are published.
Primary completion2025-06-19Actual
Enrollment · participants92Actual
Source updated2026-06-10Last update listed in the registry record
No recorded changes are available for this view and time period. Our history may be incomplete; this does not establish that the trial stayed unchanged.